Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB) Ended

2024-511446-39-00 Dementia with Lewy Bodies (DLB) 4 2024-08-02
A study to learn if UCB3101 is safe and how it moves through the body of healthy participants Ended

2023-504586-24-00 Healthy Participants 1 2024-07-31
Prospective pilot trial to address the feasibility and safety of treatment with oral Zinc in GNAO1 associated disorders (ZINCGNAO1) Ended

2024-512735-72-00 GNAO1 associated disorders 4 2024-07-30
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in… Ended

2023-505851-33-00 Dravet Syndrome 5 2024-07-29
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosam… Ended

2023-507991-32-00 Epileptic seizures 2 2024-07-25
Evaluation of safety and pharmacokinetic parameters of the PTI5803 product Ended

2024-512472-35-00 Epilepsy 3 2024-07-23
Lu AF28996 in Patients With Parkinson's Disease Ended

2023-507785-12-00 Parkinson's Disease 3 2024-07-22
A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX31… Ended

2023-507959-29-00 Parkinson’s Disease 3 2024-07-19
A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodec… Ended

2023-505086-83-00 Tourette Syndrome 4 2024-07-10
“A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended

2023-503289-22-00 Relapsing Multiple Sclerosis 4 2024-07-05
Conducting a quality study of the medicinal product - Vortioxetine Ended

2023-509946-36-00 No therapeutic indication in the current trial with hea 2 2024-06-29
A randomized, placebo-controlled, double blind, multiple ascending dose, phase 1 study to evaluate the safety, tolerability, and pharmacokin… Ended

2024-513127-16-00 NA - healthy volunteers 3 2024-06-24
A Phase 1, Open-Label Study to Investigate the TARP-ɣ8 Receptor Occupancy of RAP-219 Using a TARP-γ8 PET Tracer in Healthy Adult Participant… Ended

2024-512151-21-00 Epilepsy 3 2024-06-19
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy. Ended

2023-504892-25-00 Narcolepsy 5 2024-06-14
AMX0035 and Progressive Supranuclear Palsy Ended

2023-505893-14-00 Progressive Supranuclear Palsy 5 2024-06-04
Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to… Ended

2024-512311-41-00 Parkinson´s disease 2 2024-06-03
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Te… Ended

2023-509077-23-00 Ataxia Telangiectasia 5 2024-06-03
A Randomized, double-blind, placebo-controlled, three-way cross-over study to assess the pharmacodynamic effects of an authorised and a new … Ended

2024-510721-26-00 neuropathic pain 3 2024-05-17
A prospective, single-centre, randomised, double-blind, placebo-controlled, phase I, First-In-Human (FIH) trial evaluating the safety and to… Ended

2024-511426-31-00 Apathy in neurodegenerative disorders 1 2024-05-16
A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants Ended

2024-511405-27-00 Amyotrophic lateral sclerosis and Alzheimer’s disease 3 2024-05-08
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended

2023-505083-11-01 Alzheimer's Disease 4 2024-05-07
A Single-Ascending-Dose Study of MK6916 in Healthy Participants Ended

2024-510971-39-00 Acute and chronic Pain 1 2024-05-03
Randomised, crossover bioequivalence clinical trial of donepezil 5 mg capsules vs donepezil 5 mg film-coated tablets, after a single oral do… Ended

2023-506938-68-00 Alzheimer's disease 2 2024-05-03
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Ended

2023-510127-30-00 Relapsing Remitting Multiple Sclerosis (RRMS) 1 2024-04-17